Cargando…

Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo

Gefitinib resistance has been shown to complicate cancer therapy. Lovastatin is a proteasome inhibitor that enhances gefitinib-induced antiproliferation in non-small cell lung cancer. The objective of this study is to investigate the mechanism of lovastatin-induced antiproliferation in gefitinib-res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Sheng-Huei, Lin, Hung-Yun, Chang, Vincent H.S., Chen, Chien-Chung, Liu, Yun-Ru, Wang, Jinghan, Zhang, Keqiang, Jiang, Xiaoqing, Yen, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695157/ https://www.ncbi.nlm.nih.gov/pubmed/26160843

Ejemplares similares

Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma
por: Yang, Sheng-Huei, et al.
Publicado: (2015)

Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma
por: Wang, Jinghan, et al.
Publicado: (2015)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Lovastatin Induces Multiple Stress Pathways Including LKB1/AMPK Activation That Regulate Its Cytotoxic Effects in Squamous Cell Carcinoma Cells
por: Ma, Laurie, et al.
Publicado: (2012)

TNFα inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFα signaling
por: Ma, Li, et al.
Publicado: (2019)

Lovastatin‐mediated MCF‐7 cancer cell death involves LKB1‐AMPK‐p38MAPK‐p53‐survivin signalling cascade
por: Huang, Shiu‐Wen, et al.
Publicado: (2019)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
por: Ueno, Y, et al.
Publicado: (2005)

Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy
por: Dai, Lijun, et al.
Publicado: (2021)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma
por: Hsieh, Cheng-Han, et al.
Publicado: (2020)

Structural basis for the biosynthesis of lovastatin
por: Wang, Jialiang, et al.
Publicado: (2021)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Microbial Production and Biomedical Applications of Lovastatin
por: Seenivasan, A., et al.
Publicado: (2008)

The role of lovastatin in the attenuation of COVID-19
por: Karampoor, Sajad, et al.
Publicado: (2021)

Effects of Lovastatin on Brain Cancer Cells
por: Amadasu, Efosa, et al.
Publicado: (2022)

Differences Between Lovastatin and Simvastatin Hydrolysis in Healthy Male and Female Volunteers: Gut Hydrolysis of Lovastatin is Twice that of Simvastatin
por: Vree, Tom B., et al.
Publicado: (2003)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)

6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells
por: Kim, Tae Woo, et al.
Publicado: (2023)

Lovastatin, an Up-Regulator of Low-Density Lipoprotein Receptor, Enhances Follicular Development in Mouse Ovaries
por: Kim, Yu Jin, et al.
Publicado: (2023)

Micro-Osteoperforations Induce TNF-α Expression and Accelerate Orthodontic Tooth Movement via TNF-α-Responsive Stromal Cells
por: Kinjo, Ria, et al.
Publicado: (2022)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Oral Lovastatin Attenuates Airway Inflammation and Mucus Secretion in Ovalbumin-Induced Murine Model of Asthma
por: Liou, Chian-Jiun, et al.
Publicado: (2014)

Lovastatin Protects against Experimental Plague in Mice
por: Ayyadurai, Saravanan, et al.
Publicado: (2010)

Improved bioavailability through floating microspheres of lovastatin
por: Kumar, S., et al.
Publicado: (2011)

Lovastatin‐Mediated Changes in Human Tendon Cells
por: Kuzma‐Kuzniarska, Maria, et al.
Publicado: (2015)

Optimization of lovastatin production from Aspergillus fumigatus
por: Mouafi, Foukia E., et al.
Publicado: (2016)

Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
por: Gaber, Dalia A
Publicado: (2020)

A Novel TNF-α-Targeting Aptamer for TNF-α-Mediated Acute Lung Injury and Acute Liver Failure
por: Lai, Wei-Yun, et al.
Publicado: (2019)

Lovastatin Differentially Regulates α7 and α4 Neuronal Nicotinic Acetylcholine Receptor Levels in Rat Hippocampal Neurons
por: Borroni, Virginia, et al.
Publicado: (2020)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
por: Jeong, Inae, et al.
Publicado: (2019)

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
por: Liu, Zhe, et al.
Publicado: (2021)

Characterization of Two Novel Cell Lines with Distinct Heterogeneity Derived from a Single Human Bile Duct Carcinoma
por: Wang, Jinghan, et al.
Publicado: (2013)

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer
por: Deng, Jiehui, et al.
Publicado: (2021)

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
por: Zhou, Wei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vlcor45r3eitf3d61al4i4hkeg